Abstract
The Innovation Institute—a for-profit company comprising six member-owner health systems—announced it has chosen 2bPrecise to leverage its cloud-based, EHR-agnostic platform to deliver pharmacogenomics information to the clinical point of care for the Institute’s members, as well as other health systems outside the network.
Under the terms of the agreement, 2bPrecise will leverage its precision medicine platform to allow clinicians to access the information from GeneFolio, a pharmacogenomics test and knowledge base developed by Avera Health—an Institute member—to help guide medication selection for individual patients based on their genetic profile.
“Pharmacogenomics is poised for rapid healthcare adoption to improve treatment success and Avera has been developing and advancing the integration for almost a decade,” said Krista Bohlen, director of personalized medicine at the Avera Institute for Human Genetics, in a prepared statement.
Delivery of the results to clinicians via the 2bPrecise platform is not only within Avera’s network in the Midwest, but also to the other five members of The Innovation Institute comprising 125 hospitals in 20 states. Other members include Bon Secours Health System, CHOC Children’s, Franciscan Missionaries of Our Lady, Mercy Health, and Providence St. Joseph Health.
pe-art / Getty Images
